News
Resuming DOAC therapy in AF patients after gastrointestinal bleed
November 15, 2018
For patients who develop a gastrointestinal bleed (GIB) while using direct oral anticoagulant (DOAC) therapy for atrial fibrillation (AF), does the risk of venous thromboembolism (VTE) or recurrent GIB increase after DOAC resumption?
News
New pediatric therapies show promise for influenza, multidrug-resistant pathogens
November 14, 2018
ORLANDO – Baloxavir, a recently approved fast-acting single-dose medication for influenza, is currently under study in children.
News
Preop anemia management saves blood, costs
November 14, 2018
BOSTON – Managing anemia prior to cardiac surgery saved a hospital more than $100,000 in transfusion costs in a pilot program.
News
Children are vulnerable to diseases emerging because of climate change
November 13, 2018
ORLANDO – Children are more vulnerable to the health impacts of climate change because of the increased exposure they have to the environment.
Opinion
Dialysis decision in elderly needs to factor in comorbidities
November 13, 2018
Palliative care specialist advises avoiding age cutoffs, considering harms of dialysis.
News
PIONEER-HF called “practice changing” for acute decompensated heart failure
November 12, 2018
CHICAGO – In-hospital initiation of sacubitril/valsartan safely and significantly reduced heart failure rehospitalizations in the next 8 weeks.
News
Burden of atrial fibrillation associated with stroke risk
November 12, 2018
In patients with paroxysmal atrial fibrillation (PAF), is the burden of atrial fibrillation associated with increased risk of ischemic stroke?
Video
How to slash colorectal surgery infection rates
November 12, 2018
BOSTON – Change perioperative routines.
Video
PIONEER-HF secures place for sacubitril/valsartan in this heart failure doc’s practice
November 11, 2018
CHICAGO – The designated discussant for the PIONEER-HF presentation points out the importance of the results.
News
Apixaban is safest effective DOAC for stroke prevention in Afib, per AHRQ report
November 10, 2018
The agency found the lowest bleeding risk with apixaban, but cites lack of head-to-head trials as a limitation in evaluating DOACs.